Facebook Twitter LinkedIn Google Plus RSS

Pharma, testing companies announce partnership

By ,

Arno Therapeutics Inc., a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced it has signed an agreement with Clarient Diagnostic Services Inc., a GE Healthcare subsidiary, to develop a diagnostic test to identify activated progesterone receptors in endometrial cancer.

According to an announcement, Clarient is a provider of cancer diagnostic testing. Its testing services will be used in the development an investigational therapy by Arno, of Flemington.

Terms were not disclosed.

Also Popular on NJBIZ

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy